CoChat

PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer

Open access

The DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.

Abstract

The cyclic GMP-AMP synthase/stimulator of IFN genes (cGAS/STING) pathway detects cytosolic DNA to activate innate immune responses. Poly(ADP-ribose) polymerase inhibitors (PARPi) selectively target cancer cells with DNA repair deficiencies such as those caused by BRCA1 mutations or ERCC1 defects. Using isogenic cell lines and patient-derived samples, we showed that ERCC1-defective non-small cell lung cancer (NSCLC) cells exhibit an enhanced type I IFN transcriptomic signature and that low ERCC1 expression correlates with increased lymphocytic infiltration. We demonstrated that clinical PARPi, including olaparib and rucaparib, have cell-autonomous immunomodulatory properties in ERCC1-defective NSCLC and BRCA1-defective triple-negative breast cancer (TNBC) cells. Mechanistically, PARPi generated cytoplasmic chromatin fragments with characteristics of micronuclei; these were found to activate cGAS/STING, downstream type I IFN signaling, and CCL5 secretion. Importantly, these effects were suppressed in PARP1-null TNBC cells, suggesting that this phenotype resulted from an on-target effect of PARPi on PARP1. PARPi also potentiated IFN-γ-induced PD-L1 expression in NSCLC cell lines and in fresh patient tumor cells; this effect was enhanced in ERCC1-deficient contexts. Our data provide a preclinical rationale for using PARPi as immunomodulatory agents in appropriately molecularly selected populations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci123319

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 61 references

Research works printed but not linked: 1

  1. Robillard L. Preclinical evaluation of the PARP inhibitor rucaparib in combination with PD-1 PD-L1 inhibition in a syngenic BRCA2 mutant ovarian cancer model. Proceedings of the AACR. 2017;58(pt A):3650. Accessed January 7, 2019.

Cited by

Items 101–200 of 338

Metadata

Authors
Chabanon, R. M., Muirhead, G., Krastev, D. B., Adam, J., Morel, D., Garrido, M., Lamb, A., Hénon, C., Dorvault, N., Rouanne, M., Marlow, R., Bajrami, I., Cardeñosa, M. L., Konde, A., Besse, B., Ashworth, A., Pettitt, S. J., Haider, S., Marabelle, A., Tutt, A. N. J., Soria, J.-C., Lord, C. J., & Postel-Vinay, S.
Affiliations
  • Université Paris-Sud (FR)
  • Breast Cancer Now (GB)
  • Institute of Cancer Research (GB)
  • Inserm (FR)
  • Sage Bionetworks (US)
  • King's College London (GB)
  • University of California, San Francisco (US)
Venue
Journal of Clinical Investigation
Published
2019-02-11
Volume
129
Issue
3
Pages
1211-1228
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W2908418801
Cited by
332
References
62
Citations by year
2026: 31 · 2025: 36 · 2024: 39 · 2023: 45 · 2022: 43 · 2021: 61 · 2020: 54 · 2019: 22
FWCI
12.97
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Research Portal (King's College London) (submittedVersion)
Funders
  • AstraZeneca
  • Sanofi
  • Merck KGaA
  • Les Laboratories Pierre Fabre
  • Fondation Philanthropia
  • Cancer Research UK (14276, 25237, 24439)
  • Institut National de la Santé et de la Recherche Médicale (INCa-DGOS-INSERM_12551)
  • Institut National Du Cancer (INCa-DGOS-INSERM-12551)
  • Institut Gustave-Roussy
  • Direction Générale de l’offre de Soins
  • Servier
Topics
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
  • Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
PARP inhibitors, non-small cell lung cancer, triple-negative breast cancer, cGAS-STING pathway, cytosolic DNA sensing, type I interferon, PARP1, micronuclei, RANTES, PD-L1 expression, lymphocyte infiltration, olaparib, rucaparib, DNA repair deficiency
MeSH terms
Poly(ADP-ribose) Polymerase Inhibitors, Poly (ADP-Ribose) Polymerase-1, A549 Cells, STING Protein, Cyclic Guanosine Monophosphate-Adenosine Monophosphate Synthase, Carcinoma, Non-Small-Cell Lung, DNA-Binding Proteins, Endonucleases, Female, Humans, Interferon-gamma, Lung Neoplasms, Membrane Proteins, Nucleotidyltransferases, BRCA1 Protein, B7-H1 Antigen, Triple Negative Breast Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.